Umeclidinium/fluticasone furoate

Drug Profile

Umeclidinium/fluticasone furoate

Alternative Names: Fluticasone furoate/umeclidinium; GSK 685698/GSK 573719

Latest Information Update: 02 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Androstadienes; Antiallergics; Antiasthmatics; Benzhydryl compounds; Bronchodilators; Glucocorticoids; Quinuclidines; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 02 Mar 2016 Umeclidinium/fluticasone furoate is in phase II development for Asthma COPD overlap syndrome
  • 01 Apr 2012 Phase-II clinical trials in Asthma in USA, Argentina, Chile, Thailand and Russia (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top